Finerenone
This medication blocks a hormone receptor called the mineralocorticoid receptor, reducing inflammation and scarring in the heart and kidneys. It is used to slow the progression of chronic kidney disease in adults with type 2 diabetes and to reduce the risk of heart failure.
Peso Molecular
378,4000 g/mol
LogP
2,40
TPSA
110,00 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C(N)=O)=C(C)N2
InChI
InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1
Molecular Formula
C21H22N4O3
HBD / HBA
2 / 6
Ligações Rotacionáveis
5
Átomos Pesados
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
This medication blocks a hormone receptor called the mineralocorticoid receptor, reducing inflammation and scarring in the heart and kidneys. It is used to slow the progression of chronic kidney disease in adults with type 2 diabetes and to reduce the risk of heart failure.
Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.
Yes, Finerenone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2181927. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 60150535. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="finerenone"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/finerenone/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/finerenone/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/finerenone/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="finerenone"></drugfyi-drug>